Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

Journal of drugs in dermatology : JDD

Volumn 3, Issue 1, 2004, Pages 27-38

  Menter, Alan ^a   Kosinski, Mark ^a   Bresnahan, Brian W ^a   Papp, Kim A ^a   Ware Jr , John E ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITALIZATION; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PSORIASIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1842591940     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)